A 39-year-old man with ulcerative colitis for 10 years and treated with 5-ASA has also primary sclerosing cholangitis (PSC) for the last 5 years. He has experienced several episodes of cholangitis treated with antibiotics. He had a successful liver transplantation 13 months ago. He is on standard immunosuppressive treatment post liver transplantation as well as continued 5-ASA treatment. There are no gastrointestinal symptoms and normal fecal-calprotectin.

Which of the following statements regarding colorectal cancer risk after liver transplantation in PSC patients is correct?